It is interesting to note that the Ago-miR-183-5p mimics and Antagomir-miR-183-5p inhibitor also have a major impact on cardiac hypertrophy and dysfunction upon pressure overload regardless of Aggf1 expression or AGGF1 protein treatment, respectively (Figs. 7 and 8). This evidence concerns the gene AGGF1 and cardiac hypertrophy.